1.
First case of drug eruption due to ipragliflozin: Case report and review of the literature.
Saito-Sasaki, N, Sawada, Y, Nishio, D, Nakamura, M
The Australasian journal of dermatology. 2017;(3):236-238
Abstract
Ipragliflozin is a new drug for the treatment of diabetes mellitus. Its action of sodium-glucose cotransporter 2 (SGLT2) inhibition induces glucosuria and decreases blood glucose levels. We report the first case of ipragliflozin-related eczematous drug eruption and a review of the past literature on drug eruptions caused by SGLT2 inhibitors.